Medical device companies are fine with paying higher user fees as long as it leads to a more predictable, streamlined process, reports the Record of Hackensack, NJ. "Enactment will help ensure that the agency has the resources necessary to fully evaluate medical device and diagnostic innovations and provide patients with timely access to medical technologies that can improve and save lives," a Becton Dickinson spokeswoman told the paper.Yesterday's public meeting on MDUFMA II did not produce any news of significance, according to several who were there. The table is set for a smooth Congressional approval process for MDUFMA itself. However, since it is bundled with controversial drug-industry legislation, it will not be passed quietly.